The ICE3 Trial
We are dedicated to providing reliable clinical support for ProSense™, so that physicians and other stakeholders can adopt the technology with confidence as the gold standard in tumor therapy.
ICE3 – PROMISING EARLY EVALUATION
ICE3 is the largest controlled multilocation clinical trial ever performed for nitrogen-based cryoablation of small, low-risk, early stage malignant breast tumors without subsequently removing them. The trial began in 2014 and has completed recruitment and cryoablation of 200 patients in 19 hospitals and medical centers across the US, including Columbia University Medical Center and Mount Sinai Beth Israel.
AN INITIAL EVALUATION OF THE ICE3 TRIAL WAS PRESENTED AT THE ANNUAL MEETING OF THE AMERICAN SOCIETY OF BREAST SURGEONS.
at least 3 years
100% Safe procedure
No significant device-related adverse events or complications have been reported
95% Patient and doctor satisfaction with cosmetic results
No scarring or change to the shape and size of the breast
76% Resumed daily lives within
48 hours of procedure
All patients released home on the day of the procedure
“Improved screening allows physicians to identify breast cancer earlier, when it’s smaller. Advances in molecular profiling (tumor biology) help us better determine which breast cancers have higher or lower risks of recurrence. We can then individualize approaches to treatment. Now with the ICE3 study, we may have the first effective non-surgical treatment option for some low risk patients.”
Richard E. Fine, MD, FACS, Director of Education and Research and practicing breast surgeon at West Cancer Center’s Comprehensive Breast Center, TN and ICE3 Investigator
ProSense™ is commercially available in the US, Europe, Hong Kong, Thailand, Singapore, Central America and South America.
Contact us for details